Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 30, 2006. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share transaction data:
- Shares Purchased: 845,000 Ordinary shares of 25 pence each.
- Purchase Date: May 30, 2006.
- Purchase Price: 1,477.01 pence per share.
- Treasury Holdings Post-Purchase: 167,484,678 shares.
- Shares in Issue (excluding Treasury): 5,814,643,116 shares.
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 845,000 shares to be held in Treasury, increasing its total Treasury holdings to approximately 167.5 million shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (845,000 shares at 1,477.01 pence) against the company's cash position in broader financial reports.
- Confirm the updated share count of 5,814,643,116 shares in issue for earnings per share calculations.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authorization.